Willink Biochemical Genetics Unit

The Willink Biochemical Genetics Unit is the main diagnostic laboratory for metabolic diseases in the North of England, based at Central Manchester University Hospitals.  

The group have access to the largest cohort of patients in Europe for lysosomal storage and mucopolysaccharide diseases, and are actively researching novel biomarkers, diagnostic tests and end point patient care and treatment.

In particular, the Willink team have extensive experience of enzyme replacement therapy in metabolic disease patients. Central Manchester University Hospitals was the main site for the phase III study which led to FDA and EMEA approval of the drug Aldurazyme as a therapy for mucopolysaccharide type I. Since approval, over 50 patients have been treated with Aldurazyme at Royal Manchester Children’s Hospital.

The close integration of laboratory investigation and clinical care has led to the development of a unique service aimed at the early diagnosis and appropriate management of affected children.

For more information please visit the Genetic Medicine website